title: Clinical efficacy and safety of Lyprinol, a patented extract from New Zealand green-lipped mussel (Perna Canaliculus) in patients with osteoarthritis of the hip and knee: a multicenter 2-month clinical trial.
abstract: OBJECTIVE
  To validate the clinical efficacy and safety of Lyprinol (a patented extract from Perna Canaliculus), a 5-LOX inhibitor in patients with osteoarthritis.
  
  
  METHODS
  In this multicenter trial, 60 patients with symptomatic osteoarthritis of the knee and hip were included to receive Lyprinol at a dose of 2 capsules twice a day. After a 4- and 8-week treatment period, the following parameters were analyzed: visual analogue scale; Lequesne functional index; global assessment by patients; global assessment by physician; and adverse effects.
  
  
  RESULTS
  Lyprinol treatment led to significant improvement of the signs and symptoms of osteoarthritis as determined by all efficacy measures. After a 4- and 8-week treatment period, 53% and 80% (respectively) of patients experienced significant pain relief, and improvement of joint function. There was no reported adverse effect during this clinical trial.
  
  
  CONCLUSIONS
  Lyprinol was very effective and is a promising anti-inflammatory product that relieves the signs and symptoms of osteoarthritis, without adverse effect.
authors.affiliation: Yonsei Medical Clinic, Seoul, Korea.
authors.forename: Se Haeng
authors.initials: SH
authors.lastname: Cho
authors.forename: Young Bok
authors.initials: YB
authors.lastname: Jung
authors.forename: Sang Cheol
authors.initials: SC
authors.lastname: Seong
authors.forename: Hyung Bin
authors.initials: HB
authors.lastname: Park
authors.forename: Ki Yong
authors.initials: KY
authors.lastname: Byun
authors.forename: Dong Chul
authors.initials: DC
authors.lastname: Lee
authors.forename: Eun Kyoo
authors.initials: EK
authors.lastname: Song
authors.forename: Jung Hwan
authors.initials: JH
authors.lastname: Son
mesh_terms: D000368:Aged; D000818:Animals; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000009:adverse effects / Q000627:therapeutic use*; D049872:Bivalvia / Q000737:chemistry; D015525:Fatty Acids, Omega-3 / Q000009:adverse effects / Q000627:therapeutic use; D005260:Female; D006801:Humans; D020024:Leukotriene Antagonists / Q000009:adverse effects / Q000627:therapeutic use*; D008055:Lipids / Q000009:adverse effects / Q000627:therapeutic use*; D016859:Lipoxygenase Inhibitors; D008297:Male; D008875:Middle Aged; D015207:Osteoarthritis, Hip / Q000188:drug therapy*; D020370:Osteoarthritis, Knee / Q000188:drug therapy*; D012449:Safety; D014020:Tissue Extracts / Q000627:therapeutic use; D016896:Treatment Outcome
chemical_list: D000894:Anti-Inflammatory Agents, Non-Steroidal; D015525:Fatty Acids, Omega-3; D020024:Leukotriene Antagonists; D008055:Lipids; D016859:Lipoxygenase Inhibitors; D014020:Tissue Extracts; C418997:lyprinol